

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark									
						A	B	C	D	E	F	G	H	I	J
						Permissions delayed/denied	Suspended by sponsor	Closed by sponsor	Sponsor Delays	Staff availability issues	No patients seen	No patients consented	Contracting delays	Rare diseases	Other
11/SC/0059	74662	INCA 2201, INC 424 - A Phase IB, Open-Label, Dose-Finding Study Of The JAK-inhibitor INC424 Tablets Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) Or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) And Baseline Platelet Counts => 50x 10 9/L nad < 100 x 10 9/L	20/10/2015		No							Y			
15/LO/0519	176955	A Multiarm-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1	27/10/2015		No							Y			
15/NW/0668	173723	FUTURE 5: A phase III, randomised, double-blind, placebo controlled multicentre study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficiency (including inhibition of structural damage), safety and tolerability up to 2	05/11/2015		No							Y			
14/WM/1170	161147	Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and highrisk oropharyngeal cancer	10/11/2015		No									Y	
14/EM/0121	143800	RITUXILUP - An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis	16/12/2015		No		Y								
13/EM/0462	136755	RomiCar: Phase I/II study to determine the MTD and overall response rate of the combination of romidepsin and carfilzomib in relapsed / refractory peripheral T-cell lymphoma	18/12/2015		No						Y				
13/LO/0706	119677	UK Multicentre Study of Children with Opsoclonus Myoclonus Syndrome (UMSCOM)	15/02/2016		No						Y				
13/SC/0436	108256	ASAP - Adjuvant Steroids in Adults with Pandemic Influenza	18/02/2016		No						Y				
14/LO/2011	159926	DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	23/11/2015	16/05/2016	No				Y			Y			
15/LO/1236	183416	A Phase 3, Randomized, Multicenter, DoubleBlind, PlaceboControlled, 2Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	15/04/2016		No						Y				
14/LO/1426	158013	NCRN - 2960 - Unresected Stage IIIB - IVM1a Melanoma Treated with Talimogene Laherparepvec	21/12/2015	02/06/2016	No							Y			
16/SC/0151	196060	A Multicentre Randomised Controlled Trial of Induced Endometrial Trauma In Women Undergoing First Time In Vitro Fertilisation (IVF)				Y									
05/MRE00/74	15072	Genetic disorders of human brain development	27/04/2016		No									Y	
15/NS/0093	171568	Hartmann's procedure versus intersphincteric APE: a prospective study	03/05/2016		No				Y	Y					
14/WM/1050	158411	A Placebo Controlled, Double-blind, Multi-centre, Repeat Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery	04/05/2016		No				Y						

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark									
						A Permissions delayed/denied	B Suspended by sponsor	C Closed by sponsor	D Sponsor Delays	E Staff availability issues	F No patients seen	G No patients consented	H Contracting delays	I Rare diseases	J Other
16/LO/0521	191745	MEDI4736 in DLBCL - A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma							Y				Y		
16/LO/0924	201676	Eight week pilot study of HFAO in COPD		19/07/2016					Y				Y		
15/WS/0011	122822	A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI-002)									Y				
15/WM/0359	187315	Achilles Tendinopathy Management (ATM)										Y			
15/NW/0545	156861	DexEnceph: A pragmatic, randomised, controlled, observer-blind trial comparing clinical outcomes in adults who receive dexamethasone alongside standard treatment versus standard treatment alone for Herpes Simplex Virus encephalitis	24/06/2016		No									Y	
15/EM/0291	169397	A WebBased Cardiac REhabilitatioN Alternative for Those Declining or Dropping Out Of Conventional Rehabilitation: The WREN Feasibility Study	07/10/2015	11/01/2016	No							Y			
15/EE/0435	191299	Stratified Treatment Optimisation for HCV-1 (STOP-HCV-1)	13/05/2016	19/09/2016	No				Y						
16/EE0048	192528	A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthma	13/05/2016	15/08/2016	No				Y						
15/LO/0485	138945	The prevention of pre-term birth in women who develop a short cervix. A multicentre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal progesterone.	09/03/2016	06/06/2016	No					Y					
14/SC/0171	120104	A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours	15/12/2015	08/03/2016	No						Y				
15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	08/12/2015	01/03/2016	No						Y				
16/EM/0007	190428	Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based		17/08/2016							Y				
14/SC/1346	151280	Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	27/06/2016		No				Y						
16/LO/0286	188120	The CELEB trial: Comparative Effectiveness of Lung volume reduction surgery for Emphysema and Bronchoscopic lung volume reduction with valve placement.	26/05/2016	09/08/2016	No							Y			
15/LO/1120	179128	PENTA 20 (ODYSSEY) (Once daily dolutegravir in young people vs standard therapy)	20/07/2016		No										Y

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark										
						A Permissions delayed/denied	B Suspended by sponsor	C Closed by sponsor	D Sponsor Delays	E Staff availability issues	F No patients seen	G No patients consented	H Contracting delays	I Rare diseases	J Other	
15/YH/0535	190077	A multicenter, randomized, open label, parallel group study comparing pre-discharge and postT-discharge tTreatment initiation with LCZ696 in heArt failure patieNtS with reduced ejection-fraction hospitalized for an acute decompensation eveNt (ADHF) (the TRANSITION study)		11/08/2016												
15/EM/0473	187884	Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed	24/03/2016	01/06/2016	Yes											
15/NW/0626	184626	DIAB 4826	21/04/2016	29/06/2016	Yes											
16/EM/0041	197706	SOLAR-1: alpelisib + fulvestrant in advanced breast cancer	12/04/2016	20/06/2016	Yes											
16/EM/0221	196697	Pre-Start Phase 2	10/07/2016	15/09/2016	Yes											
15/NW/0090	162325	Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus	26/10/2015	28/12/2015	Yes											
15/EM/0055	167115	Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2	13/10/2015	15/12/2015	Yes											
15/EM/0323	76077	LCH - IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	29/07/2016		Within 70 Days											
14/LO/2163	191851	Pomalidomide in relapsed and refractory multiple myeloma (RRMM)	12/04/2016	14/06/2016	Yes											
16/NE/0014	192732	A 12-Week Study to Assess the Efficacy and Tolerability of AF-219 in Subjects with Treatment Refractory Chronic Cough	11/04/2016	13/06/2016	Yes											
15/NW/0468	182025	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 inCombination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia	20/01/2016	22/03/2016	Yes											
14/SC/1206	142485	ElaTION	11/12/2015	10/02/2016	Yes											
15/LO/1500	187068	Drug-drug interaction study with nintedanib and pirfenidone	18/04/2016	17/06/2016	Yes											
14/YH/1259	163195	ALPHA.	22/06/2016	19/08/2016	Yes											
15/SC/0699	192903	MUSC 5128	05/08/2016		Within 70 Days											
16/WM/0001	190802	World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip	05/08/2016		Within 70 Days											
15/YH/0212	174222	RCT Rehab for plantar fasciitis (hamstring stretches)	12/02/2016	07/04/2016	Yes											
16/EM/0006	191553	A 24 week, Multicentre, Randomized, Open Label, 2 ARM Parallel-group study evaluating the Efficacy and Safety of Patient - versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus	22/04/2016	15/06/2016	Yes											

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark										
						A Permissions delayed/denied	B Suspended by sponsor	C Closed by sponsor	D Sponsor Delays	E Staff availability issues	F No patients seen	G No patients consented	H Contracting delays	I Rare diseases	J Other	
14/NW/1067	137736	PROteKT	01/10/2015	23/11/2015	Yes											
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatumimab in Combination with	16/11/2015	08/01/2016	Yes											
13/EM/0118	101849	A multicentre randomised placebo controlled trial of prophylactic enteral lactoferrin supplementation to prevent late onset invasive infection in very preterm infants. ELFIN.	23/11/2015	14/01/2016	Yes											
16/EE/0011	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN ASA SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	29/03/2016	20/05/2016	Yes											
14/EM/1174	158992	PD-HF	09/08/2016		Within 70 Days											
16/LO/0448	198164	A Phase 2 Study of LY2606368 in patients with extensive stage disease small cell lung cancer.	09/08/2016		Within 70 Days											
15/NW/0507	178583	A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 as add-on therapy over 24 weeks in patients with severe persistent asthma.	11/11/2015	01/01/2016	Yes											
15/LO/1595	183040	PRISM	31/05/2016	08/06/2016	Yes											
16/EM/0193	190690	Dal-GenE Trial	21/07/2016	09/09/2016	Yes											
15/LO/0183	170760	STRIVE HF	07/10/2015	25/11/2015	Yes											
15/NW/0319	174853	A phase 3, randomized, double-blind, placebo-group, multicenter study to evaluate the efficacy, safety, and tolerability of LX4211 as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy	20/10/2015	07/12/2015	Yes											
14/WA/1054	136117	A randomised phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma (MPM)	03/05/2016	20/06/2016	Yes											
16/LO/0092	194133	GO29834	29/07/2016	14/09/2016	Yes											
16/WM/0009	182266	A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Canagliflozin	11/07/2016	23/08/2016	Yes											
14/NI/1120	149397	EDNA	14/09/2015	26/10/2015	Yes											
14/YH/1199	153953	galactic	02/06/2016	14/07/2016	Yes											
15/WM/0222	182089	The DIASTOLIC Study	02/10/2015	12/11/2015	Yes											
16/NW/0169	196447	An open-label, randomised, phase II study comparing TAS-102 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are eligible for non-intensive therapy	19/05/2016	21/07/2016	Yes											
14/YH/0128	150031	SaFaRI (SNS versus the FENIX MSA for adult FI)	22/08/2016		Within 70 Days											

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark										
						A Permissions delayed/denied	B Suspended by sponsor	C Closed by sponsor	D Sponsor Delays	E Staff availability issues	F No patients seen	G No patients consented	H Contracting delays	I Rare diseases	J Other	
16/EM/0005	186752	HYDRation and bicarbonate to prevent acute Renal injury after endovascular Aneurysm repair	31/03/2016	09/05/2016	Yes											
13/LO/0822	108709	VinCaP - A phase II trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis	23/08/2016		Within 70 Days											
15/EM/0313	168769	Gene expression profiling in asthma	20/01/2016	24/02/2016	Yes											
15/LO/1419	183975	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	15/06/2016	19/07/2016	Yes											
15/NI/0161	184748	Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis	10/03/2016	11/04/2016	Yes											
15/WM/0263	184150	An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects with Relapsed/Refractory B-cell malignancies	06/11/2015	08/12/2015	Yes											
14/EE/1293	164389	C-STICH	26/05/2016	27/06/2016	Yes											
16/EM/0165	203281	A Phase 3 Multicenter Open-label Study of Brigatinib versus Crizotinib		06/09/2016												
12/EE/0230	102101	RITAZAREM	12/01/2016	12/02/2016	Yes											
14/SS/1087	164169	RENA4131	13/06/2016	14/07/2016	Yes											
14/LO/1428	156358	A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetate) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma; the adjunctive steroid combination in ocular trauma (ASCOT) trial	01/09/2016		Within 70 Days											
15/SC/0475	174852	An Open-Label, Randomized Phase 3 Trial of Nivolumab and Nivolumab plus Ipilimumab versus Platinum Doublet Chemotherapy in Patients with Chemotherapy-Na?ve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	21/01/2016	17/03/2016	Yes											
15/LO/2100	192155	RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS	19/04/2016	20/05/2016	Yes											
13/WS/0119	117753	T-TIME	02/09/2016		Within 70 Days											
16/LO/0152	193306	DIAB 5013 A real-world, point of care, randomized, 2-arm, open, 52-week study to evaluate the effect of a digital disease management support tool in patients with type 2 diabetes mellitus.	13/04/2016	10/05/2016	Yes											
15/WS/0135	183471	A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 Combined with Idelalisib in Subjects with B-cell Malignancies	09/11/2015	02/12/2015	Yes											
15/EM/0259	167328	GO for IT	20/10/2015	12/11/2015	Yes											
15/EM/0325	171407	Model-based versus traditional warfarin dosing in children	14/10/2015	02/11/2015	Yes											

01/10/2015 to 30/09/2016

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met? (Yes or No)	Reasons for not achieving the 70 day benchmark									
						A Permissions delayed/denied	B Suspended by sponsor	C Closed by sponsor	D Sponsor Delays	E Staff availability issues	F No patients seen	G No patients consented	H Contracting delays	I Rare diseases	J Other
15/EM/0433	181453	The feasibility of a homebased sedentary behaviour intervention for hospitalised chronic obstructive pulmonary disease (COPD) patients following an acute exacerbation: Sitting and Exacerbations Trial (COPDSEAT)	14/01/2016	02/02/2016	Yes										
07/80706/81	46584	Molecular mechanisms and pathways of chronic inflammatory and degenerative diseases. (Dupuytren's 1) - (Dupuytren's 1)	13/11/2015	01/12/2015	Yes										
15/YH/0286	178790	Treating neovascular age-related Macular Degeneration with Aflibercept: a pilot 24 month, multi-centre randomized controlled trial comparing Standard Care with an individualised Treat and Extend regimen.		02/08/2016							Y				
15/LO/2066	193084	4222: Efficacy And Long-Term Safety Of Oral Semaglutide Versus Sitagliptin In Subjects With Type 2 Diabetes Mellitus. A 78-Week, Randomised, Double-Blind, Double-Dummy, Active-Controlled, Parallel-Group, Multi-Centre, Multi-National, Four-Armed Trial	23/03/2016	10/05/2016	Yes										
14/SC/1161	155743	Prospective, single-arm, multicentre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients	29/03/2016	12/04/2016	Yes										
13/EM/0015	118772	CAN 3001 v1.0 - A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study	17/02/2016	01/03/2016	Yes										
Rec Exempt	165982	A?cluster?randomised?controlled?trial?to?investigate?the?effectiveness?and?cost?effectiveness?of?the?Girls?Active?intervention	16/10/2015	26/10/2015	Yes										
14/WA/1075	150715	HeadPoST Version 2.1	20/04/2016	06/05/2016	Yes										
15/SC/0397	183591	NJ002	23/11/2015	01/12/2015	Yes										
15/SC/0085	171841	A feasibility study with a crossover design to assess the diagnostic accuracy of acetic acid targeted biopsies versus non targeted biopsies (current practice) for detection of dysplasia during Barrett's surveillance: the ABBA study.	08/12/2015	15/12/2015	Yes										
15/EM/0048	150024	TICONC	27/10/2015	02/11/2015	Yes										
15/WM/0385	173283	Evaluation of a wireless monitoring system	11/12/2015	16/12/2015	Yes										
15/EM/0247	179169	CANC - 4517	14/10/2015	26/10/2015	Yes										
16/WM/0276	207822	Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study													